|
1
|
Höglund M: Bladder cancer, a two phased
disease? Semin Cancer Biol. 17:225–232. 2007.
|
|
2
|
Crallan RA, Georgopoulos NT and Southgate
J: Experimental models of human bladder carcinogenesis.
Carcinogenesis. 27:374–381. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Oliveira PA, Colaço A, De la Cruz PLF and
Lopes C: Experimental bladder carcinogenesis-rodent models. Exp
Oncol. 28:2–11. 2006.PubMed/NCBI
|
|
4
|
Arentsen HC, Hendricksen K, Oosterwijk E
and Witjes JÁ: Experimental rat bladder urothelial cell carcinoma
models. World J Urol. 27:313–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Grubbs CJ, Lubet RA, Koki AT, Leahy KM,
Masferrer JL, Steele VE, Kelloff GF, Hill DL and Seibert K:
Celecoxib inhibits N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced
urinary bladder cancers in male B6D2F1 mice and female Fischer-344
rats. Cancer Res. 60:5599–5602. 2000.PubMed/NCBI
|
|
6
|
Oliveira PA, Palmeira C, Lourenço LM and
Lopes CA: Evaluation of DNA content in preneoplastic changes of
mouse urinary bladder induced by N-butyl-N-(4-hydroxybutyl)
nitrosamine. J Exp Clin Cancer Res. 24:609–616. 2005.PubMed/NCBI
|
|
7
|
Williams PD, Lee JK and Theodorescu D:
Molecular credentialing of rodent bladder carcinogenesis models.
Neoplasia. 10:838–846. 2008.PubMed/NCBI
|
|
8
|
Druckrey H, Preussmann R, Ivankovic S,
Schmidt CH, Mennel HD and Stahl KW: Selective induction of bladder
cancer in rats by dibutyl-and
N-butyl-n-(4-hydroxybutyl)nitrosamine. Z Krebsforsch. 66:280–290.
1964.PubMed/NCBI
|
|
9
|
Kunze E, Schauer A and Schatt S: Stages of
transformation in the development of
N-butyl-N-(4-hydroxybutyl)-nitrosamine-induced transitional cell
carcinomas in the urinary bladder of rats. Z Krebsforch Klin Onkol
Cancer Res Clin Oncol. 87:139–160. 1976.PubMed/NCBI
|
|
10
|
Oliveira PA, Palmeira C, Colaço A, De La
Cruz PLF and Lopes C: DNA content analysis, expression of Ki-67 and
p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl)
nitrosamine and treated with mitomycin C and bacillus
Calmette-Guérin. Anticancer Res. 26:2995–3004. 2006.PubMed/NCBI
|
|
11
|
Palmeira C, Oliveira PA, Arantes-Rodrigues
R, Colaço A, De la Cruz PLF, Lopes C and Santos L: DNA cytometry
and kinetics of rat urothelial lesions during chemical
carcinogenesis. Oncol Rep. 21:247–252. 2009.PubMed/NCBI
|
|
12
|
Palmeira C, Lameiras C, Amaro T, Lima L,
Kock A, Lopes C, Oliveira PA and Santos L: CIS is a surrogate
marker of genetic instability and field carcinogenesis in the
urothelial mucosa. Urol Oncol. Oct 23–2009.(Epub ahead of
print).
|
|
13
|
Greene FL, Page DL, Fleming ID, et al:
AJCC Cancer Staging Manual. 6th edition. Springer Verlag; New York:
2002, View Article : Google Scholar
|
|
14
|
Sauter G, Algaba F, Amin M, et al: Tumours
of the urinary system: non-invasive urothelial neoplasias. WHO
Classification of Tumours of the Urinary System and Male Genital
Organs. Eble JN, Sauter G, Epstein JL and Sesterhenn I: IARCC
Press; Lyon: pp. 110–123. 2004
|
|
15
|
Lopez-Beltran A, Sauter G, Gasser T, et
al: Tumours of the urinary system: infiltrating urothelial
carcinoma. WHO Classification of Tumours of the Urinary System and
Male Genital Organs. Eble JN, Sauter G, Epstein JL and Sesterhenn
I: IARCC Press; Lyon: pp. 93–109. 2004
|
|
16
|
Santos L, Amaro T, Costa C, Pereira S,
Bento MJ, Lopes P, Oliveira J, Criado B and Lopes C: Ki-67 index
enhances the prognostic accuracy of the urothelial supeficial
bladder carcinoma risk group classification. Int J Cancer.
105:267–272. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Palmeira CA, Oliveira PA, Seixas F, Pires
MA, Lopes C and Santos L: DNA image cytometry in bladder cancer:
state of the art. Anticancer Res. 28:443–450. 2008.PubMed/NCBI
|
|
18
|
Cordon-Cardo C: Molecular alterations
associated with bladder cancer initiation and progression. Scand J
Urol Nephrol. 42:S154–S165. 2008. View Article : Google Scholar
|
|
19
|
Lacy S, Lopez-Beltran A, MacLennan GT,
Foster SR, Montironi R and Cheng L: Molecular pathogenesis of
urothelial carcinoma – the clinical utility of emerging new
biomarkers and future molecular classification of bladder cancer.
Anal Quant Cytol Histol. 31:5–16. 2009.
|
|
20
|
Margulis V, Lotan Y, Karakiewicz PI, et
al: Multi-institutional validation of the predictive value of Ki-67
labeling index in patients with urinary bladder cancer. J Natl
Cancer Inst. 101:114–119. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spiess PE and Czerniak B: Dual-track
pathway of bladder carcinogenesis. Practical implications. Arch
Pathol Lab Med. 130:844–852. 2006.PubMed/NCBI
|
